These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12175762)

  • 21. Building for an exit (or not).
    Gunning TG
    Nat Biotechnol; 2008 Sep; 26(9):971-3. PubMed ID: 18792427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioentrepreneurship around the world.
    Persidis A
    Nat Biotechnol; 1998 May; 16 Suppl():3-4. PubMed ID: 9591247
    [No Abstract]   [Full Text] [Related]  

  • 23. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 25. Silent running: the race to the clinic.
    Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract]   [Full Text] [Related]  

  • 26. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 27. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 28. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 29. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 30. Trends in biopharmaceutical IPOS: 1996-2005.
    Williams DR; Young CC
    J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 33. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech industry tries to recover from 2-year lull.
    Brower V
    J Natl Cancer Inst; 2003 Mar; 95(5):348-9. PubMed ID: 12618496
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech drugs come of age; policymakers take notice.
    Iglehart JK
    Health Aff (Millwood); 2006; 25(5):1202-3. PubMed ID: 16966714
    [No Abstract]   [Full Text] [Related]  

  • 36. Investment indicators show US is still ahead.
    Lähteenmäki R; Hodgson J
    Nat Biotechnol; 1998 Feb; 16(2):149-50. PubMed ID: 9487519
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotech at the beauty counter.
    Nasto B
    Nat Biotechnol; 2007 Jun; 25(6):617-9. PubMed ID: 17557090
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 39. Chinese biotech hamstrung by production issues.
    Jia H
    Nat Biotechnol; 2007 Feb; 25(2):147-8. PubMed ID: 17287733
    [No Abstract]   [Full Text] [Related]  

  • 40. Exit strategies in Europe.
    Buckel P; Dauer U; Frei P; Nothias JY
    Nat Biotechnol; 2006 Oct; 24(10):1195-7. PubMed ID: 17111560
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.